Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
X-37
AddedFeb 15, 2024
UpdatedJun 18, 2026
X-37

X-37

Series A

X-37: A pharmaceutical discovery and development firm, leveraging AI for innovative solutions.

HQ
San Francisco, CA, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

X-37 is a pharmaceutical discovery and development company leveraging AI to innovate drug development. Co-founded by AtomWise and pharmaceutical experts from Velocity Pharmaceutical Development, X-37 focuses on targeting difficult-to-drug proteins with high therapeutic value. Their AI-driven approach enables them to address challenging targets in autoimmune diseases, cancer, and anticoagulation, aiming to create safe and effective therapies where conventional methods have struggled.

X-37 has achieved significant milestones, including closing a $14.5 million Series A financing led by DCVC Bio, with participation from Alpha Intelligence Capital and Hemi Ventures. This funding supports their mission to revolutionize drug discovery using advanced AI technology. The company's impactful work has already sparked new hope for treating complex diseases, positioning X-37 as a leader in AI-driven pharmaceutical innovation.

X-37 - Similar Companies

DeepCure logo

DeepCure

deepcure.ai

Phronesis Artificial Intelligence logo

Phronesis Artificial Intelligence

phronesisai.com

Atomic AI logo

Atomic AI

atomic.ai

Cognaisent logo

Cognaisent

cognaisent.com

NeuroX1 logo

NeuroX1

neurox1.com

Insitro logo

Insitro

insitro.com

XtalPi logo

XtalPi

xtalpi.com

BioXcel Therapeutics logo

BioXcel Therapeutics

Iambic Therapeutics logo

Iambic Therapeutics

iambic.ai

Anagenex logo

Anagenex

anagenex.com

Model Medicines logo

Model Medicines

modelmedicines.com

Auransa logo

Auransa

auransa.com

Unnatural Products logo

Unnatural Products

Pathos AI logo

Pathos AI

pathos.com

xCures logo

xCures

xcures.com

X-37 - Quick Facts

Who are X-37's competitors?

Companies similar to X-37 include DeepCure, Phronesis Artificial Intelligence, Atomic AI and Cognaisent.

When was X-37 founded?

X-37 was founded in 2018.

Where is X-37's headquarters located?

X-37's headquarters is located in San Francisco, CA, US.

When was X-37's last funding round?

X-37's most recent funding round was for $14.5M (USD) in November 2019.

How much has X-37 raised to-date?

As of Nov 14, 2019, X-37 has raised a total of $14.5M (USD).

How many employees does X-37 have?

X-37 has 5 employees as of Feb 4, 2024.

X-37 - Classification

Ownership
  • Equity
  • Venture Capital
Technology
  • AI
  • Machine Learning
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Drug Development
Tags
  • AI Operations
  • Biotech
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7372Prepackaged Software
Show 6 more industry codes
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7371Computer Programming Services